JNCE

Why Is Jounce Therapeutics (JNCE) Stock Up 37% Today?

By William White, InvestorPlace Writer
Jounce Therapeutics (JNCE) stock is climbing higher on Wednesday after getting an unexpected acquisition bid from Concentra Biosciences.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

By William White, InvestorPlace Writer
We're beginning the day with a look at the biggest pre-market stock movers traders need to know about for Wednesday morning!

Why Is Jounce Therapeutics (JNCE) Stock Up 14% Today?

By William White, InvestorPlace Writer
Jounce Therapeutics (JNCE) stock is on the rise Thursday after the company revealed details of a merger plan with Redx Pharma.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer
We're starting off the day with a look at all the biggest pre-market stock movers traders need to know about on Thursday!

Why Is Jounce Therapeutics (JNCE) Stock Up 70% Today?

By Dana Blankenhorn, InvestorPlace Contributor
Gilead will try to win approval for what is now GS-1811, while Jounce develops other immunotherapy drugs. JNCE stock is soaring.

7 IPOs That Were Done the Right Way

By Will Ashworth, InvestorPlace Contributor
These seven IPOs take us back to the days when IPOs were about more than early investors getting a profitable exit.